SuperworthBio-Rad Laboratories profit margin BIO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 8.6%
- Operating margin, 12 months
- 2.1%
- Net margin on a year earlier
- −3.9 pts
- Peer median
- 14.1%
Over the twelve months to Jun 30, 2026, Bio-Rad Laboratories kept 8.6% of its revenue as net profit, with an operating margin of 2.1% and a gross margin of 51.9%.
The median for 10 diagnostics and research stocks of a similar size is 14.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 29.4% | 1.8% | 51.9% |
| FY2024 | −71.9% | 10.5% | 53.7% |
| FY2023 | −23.9% | 12.6% | 53.4% |
| FY2022 | n/a | 17.2% | 55.9% |
| FY2021 | n/a | 16.7% | 56.0% |
| FY2020 | n/a | 16.1% | 56.5% |
| FY2019 | 76.1% | 9.9% | 54.4% |
| FY2018 | 16.0% | −4.5% | 53.4% |
| FY2017 | 5.7% | 5.5% | 55.0% |
| FY2016 | 1.3% | 2.6% | 55.0% |
| FY2015 | 5.6% | 8.3% | 55.5% |
| FY2014 | 4.1% | 6.9% | 54.2% |
| FY2013 | 3.6% | 7.9% | 55.3% |
| FY2012 | 7.9% | 12.5% | 55.8% |
| FY2011 | 8.6% | 14.2% | 56.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 8.6% | −3.9 pts | 2.1% | |
| Q1 FY26 | 6.5% | +91.7 pts | 2.2% | |
| Q4 FY25 | 29.4% | +101.3 pts | 1.8% | |
| Q3 FY25 | −26.4% | +3.8 pts | 8.8% | |
| Q2 FY25 | 12.5% | +64.2 pts | 8.8% | |
| Q1 FY25 | −85.2% | −72.8 pts | 9.8% | |
| Q4 FY24 | −71.9% | −48.0 pts | 10.5% | |
| Q3 FY24 | −30.2% | −24.3 pts | 11.9% | |
| Q2 FY24 | −51.7% | −36.3 pts | 13.0% | |
| Q1 FY24 | −12.4% | −5.5 pts | 12.3% | |
| Q4 FY23 | −23.9% | n/a | 12.6% | |
| Q3 FY23 | −5.9% | n/a | 13.3% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Bio-Rad Laboratories' size, closest first, today.
| Company | Profit margin |
|---|---|
| BIOBio-Rad Laboratories | 8.6% |
| CAICaris Life Sciences | 10.6% |
| LNTHLantheus | 17.7% |
| RVTYRevvity | 8.2% |
| MEDPMedpace | 17.7% |
| BLLNBillionToOne | 9.5% |
| VCYTVeracyte | 20.4% |
| LHLabcorp | 7.0% |
| DGXQuest Diagnostics | 9.2% |
| CDNACareDx | 24.2% |
| MTDMettler-Toledo International | 21.9% |
| Peer median | 14.1% |
Where Bio-Rad Laboratories ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Bio-Rad Laboratories
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.